Major pharmaceutical companies, including Pfizer Inc. (NYSE: PFE) and Novo Nordisk A/S (NYSE: NVO), are ramping up their mergers and acquisitions (M&A) activity in response to an impending patent cliff that threatens to erode exclusivity on blockbuster drugs worth nearly $175 billion in annual sales over the next six years. Pfizer’s recent acquisition of Metsera, a weight-loss drug maker, underscores this trend as firms seek to bolster their portfolios ahead of potential revenue losses.
This surge in M&A activity could reshape the biotech landscape, presenting both risks and opportunities for investors. With smaller biotech firms often at the forefront of innovation, exchange-traded funds (ETFs) like the SPDR S&P Biotech ETF (NYSEARCA: XBI) and iShares Biotechnology ETF (NASDAQ: IBB) offer strategic exposure to this volatility. XBI has outperformed the broader market with an 11% year-to-date return, while IBB has lagged at 2%, despite a strong 40% return over the past year.
Investors should consider the differing strategies of these ETFs: XBI’s diversified small-cap focus versus IBB’s concentration in larger firms. As M&A activity intensifies, these funds could serve as valuable tools for navigating the evolving biotech sector.
Source: marketbeat.com